Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] Daeduck Electronics (353200) – New Facility Investment / 2026-07-20

Posted on July 20, 2026August 3, 2026 By K-STOCK Editor No Comments on [Disclosure] Daeduck Electronics (353200) – New Facility Investment / 2026-07-20

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

Daeduck Electronics decided to invest KRW 497.0B, equivalent to 55.39% of its equity, in new semiconductor manufacturing equipment and auxiliary facilities to meet growing market demand.

📊 Key Disclosure Contents & Major Figures

1. Investment Purpose and Scope

  • Investment Classification: New facility investment
  • Investment Target: Semiconductor product production facilities and auxiliary equipment
  • Investment Purpose: Facility and auxiliary investment to respond to increasing demand in the semiconductor market

2. Investment Amount and Equity Ratio

  • Investment Amount: KRW 497.0B (KRW 497,000,000,000)
  • Total Equity: KRW 897.31B (KRW 897,305,160,164) / (Based on FY2025 K-IFRS consolidated financial statements)
  • Ratio to Equity: 55.39%
  • Large Corporation Status: N/A

3. Investment Period and Financing Plan

  • Investment Period: July 20, 2026 ~ December 31, 2027
  • Financing Plan: To be funded through internal cash reserves and external borrowings

4. Board Resolution & Other Reference Details

  • Board Resolution Date: July 20, 2026
  • Board Attendance Status: Outside Directors: 1 Present, Auditor: Present
  • Investment Start Date: Board resolution date (July 20, 2026)
  • Other Matters: The investment amount and period are subject to change during implementation.

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of Facility Investment Execution and Progress

This disclosure reports the decision on new facility investments for semiconductor manufacturing equipment, along with the planned investment period and financing methods. Checking whether the facility investment and capital procurement proceed according to the disclosed schedule is important to verify whether the transaction is completed as planned. Relevant details can be verified in future subsequent disclosures or periodic reports including annual, semi-annual, or quarterly reports.

📢 Disclaimer & Source Notice

Fact Source: Financial Supervisory Service DART

Investment Risk Notice: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.

Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Semiconductors

Post navigation

Previous Post: [Disclosure] ALTEOGEN (196170) – (Correction) Decision on Bonus Issue / 2026-07-20
Next Post: [Disclosure] Hanmi Semiconductor (042700) – Corporate Value-up Plan (Voluntary Disclosure) / 2026-07-20

Related Posts

[Disclosure] SK hynix (000660) – Decision on Business Acquisition (Correction Disclosure) / 2026-02-13 Semiconductors
[Disclosure] Samsung Electro-Mechanics (009150) – Corporate Value-up Plan (Voluntary Disclosure) / 2026-03-19 Semiconductors
[Disclosure] Celltrion (068270) – Marketing Authorization Granted by South Korean MFDS for Omlyclo (CT-P39, Xolair Biosimilar) / 2024-06-24 Disclosures
[Disclosure] ISU PETASYS (007660) – Investor Relations (IR) Holding / 2026-05-20 Semiconductors
[Disclosure] Hanwha Ocean (042660) – (Correction) Loan Decision / 2025-06-30 Disclosures
[Disclosure] Samsung Biologics (207940) – (Correction) Major Management Matters Related to Investment Decisions / 2024-03-27 Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme